Kawasaki disease triggered by parvovirus infection: an atypical case report of two siblings.
Cardiotonic Agents
/ therapeutic use
Child
Coronary Aneurysm
/ drug therapy
Dobutamine
/ therapeutic use
Dopamine
/ therapeutic use
Echocardiography
Female
Humans
Immunologic Factors
/ therapeutic use
Immunosuppressive Agents
/ therapeutic use
Infant
Interleukin 1 Receptor Antagonist Protein
/ therapeutic use
Male
Parvoviridae Infections
/ complications
Parvovirus
/ isolation & purification
Shock
/ physiopathology
Siblings
Stroke Volume
Treatment Outcome
Anakinra
Kawasaki disease
Kawasaki shock syndrome
Journal
Journal of medical case reports
ISSN: 1752-1947
Titre abrégé: J Med Case Rep
Pays: England
ID NLM: 101293382
Informations de publication
Date de publication:
24 Apr 2019
24 Apr 2019
Historique:
received:
06
06
2018
accepted:
24
02
2019
entrez:
25
4
2019
pubmed:
25
4
2019
medline:
26
11
2019
Statut:
epublish
Résumé
There are reports of the familial occurrence of Kawasaki disease but only a few reports described Kawasaki disease in siblings. However, the familial cases were not simultaneous. In these patients the idea of infective agents as trigger must be considered. We describe two siblings with atypical presentations of Kawasaki disease; the sister was first diagnosed as having parvovirus infection with anemia and the brother was diagnosed as having myocarditis. The first patient was a 9-month-old Caucasian girl with fever, conjunctivitis, rash, and pharyngitis, and later she had cervical adenopathy, diarrhea and vomiting, leukocytosis, and anemia, which were explained by positive immunoglobulin M against parvovirus. However, coronary artery lesions with aneurysms were documented at day 26 after fever onset. An infusion of intravenous immunoglobulin and high doses of steroids were not efficacious to resolve the coronary lesions. She was treated with anakinra, despite a laboratory test not showing inflammation, with prompt and progressive improvement of coronary lesions. Her 7-year-old Caucasian brother presented vomiting and fever at the same time as she was unwell, which spontaneously resolved after 4 days. Four days later, he again presented with fever with abdominal pain, associated with tachypnea, stasis at the pulmonary bases, tachycardia, gallop rhythm, hypotension, secondary anuria, and hepatomegaly. An echocardiogram revealed a severe hypokinesia, with a severe reduction of the ejection fraction (20%). He had an increase of immunoglobulin M anti-parvovirus, tested for the index case of his sister, confirming the suspicion of viral myocarditis. He received dopamine, dobutamine, furosemide plus steroids, with a progressive increase of the ejection fraction to 50%. However, evaluating his sister's history, the brother showed a myocardial dysfunction secondary to Kawasaki shock syndrome. We report on familial Kawasaki disease in two siblings which had the same infectious trigger (a documented parvovirus infection). The brother was diagnosed as having post-viral myocarditis. However, in view of the two different and simultaneous evolutions, the girl showed Kawasaki disease with late coronary artery lesions and aneurysms, whereas the brother showed Kawasaki shock syndrome with myocardial dysfunction. We stress the effectiveness of anakinra in non-responder Kawasaki disease and the efficacy on coronary aneurysms.
Sections du résumé
BACKGROUND
BACKGROUND
There are reports of the familial occurrence of Kawasaki disease but only a few reports described Kawasaki disease in siblings. However, the familial cases were not simultaneous. In these patients the idea of infective agents as trigger must be considered.
CASE PRESENTATION
METHODS
We describe two siblings with atypical presentations of Kawasaki disease; the sister was first diagnosed as having parvovirus infection with anemia and the brother was diagnosed as having myocarditis. The first patient was a 9-month-old Caucasian girl with fever, conjunctivitis, rash, and pharyngitis, and later she had cervical adenopathy, diarrhea and vomiting, leukocytosis, and anemia, which were explained by positive immunoglobulin M against parvovirus. However, coronary artery lesions with aneurysms were documented at day 26 after fever onset. An infusion of intravenous immunoglobulin and high doses of steroids were not efficacious to resolve the coronary lesions. She was treated with anakinra, despite a laboratory test not showing inflammation, with prompt and progressive improvement of coronary lesions. Her 7-year-old Caucasian brother presented vomiting and fever at the same time as she was unwell, which spontaneously resolved after 4 days. Four days later, he again presented with fever with abdominal pain, associated with tachypnea, stasis at the pulmonary bases, tachycardia, gallop rhythm, hypotension, secondary anuria, and hepatomegaly. An echocardiogram revealed a severe hypokinesia, with a severe reduction of the ejection fraction (20%). He had an increase of immunoglobulin M anti-parvovirus, tested for the index case of his sister, confirming the suspicion of viral myocarditis. He received dopamine, dobutamine, furosemide plus steroids, with a progressive increase of the ejection fraction to 50%. However, evaluating his sister's history, the brother showed a myocardial dysfunction secondary to Kawasaki shock syndrome.
CONCLUSIONS
CONCLUSIONS
We report on familial Kawasaki disease in two siblings which had the same infectious trigger (a documented parvovirus infection). The brother was diagnosed as having post-viral myocarditis. However, in view of the two different and simultaneous evolutions, the girl showed Kawasaki disease with late coronary artery lesions and aneurysms, whereas the brother showed Kawasaki shock syndrome with myocardial dysfunction. We stress the effectiveness of anakinra in non-responder Kawasaki disease and the efficacy on coronary aneurysms.
Identifiants
pubmed: 31014402
doi: 10.1186/s13256-019-2028-5
pii: 10.1186/s13256-019-2028-5
pmc: PMC6480815
doi:
Substances chimiques
Cardiotonic Agents
0
Immunologic Factors
0
Immunosuppressive Agents
0
Interleukin 1 Receptor Antagonist Protein
0
Dobutamine
3S12J47372
Dopamine
VTD58H1Z2X
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104Références
Arch Pediatr Adolesc Med. 2005 Sep;159(9):876-81
pubmed: 16143748
J Vet Med B Infect Dis Vet Public Health. 2005 Sep-Oct;52(7-8):344-7
pubmed: 16316398
Pediatr Allergy Immunol. 2010 Nov;21(7):1091-2
pubmed: 20977502
Eur J Gastroenterol Hepatol. 2011 Mar;23(3):289
pubmed: 21304320
New Microbiol. 2011 Oct;34(4):421-4
pubmed: 22143818
J Am Soc Echocardiogr. 2016 Feb;29(2):150-7
pubmed: 26386984
Contemp Clin Trials. 2016 May;48:70-5
pubmed: 27080929
Curr Opin Rheumatol. 2016 Jul;28(4):383-9
pubmed: 27166925
Ital J Pediatr. 2016 Nov 2;42(1):92
pubmed: 27806720
BMC Pediatr. 2017 Apr 8;17(1):102
pubmed: 28390409
Front Pharmacol. 2017 Mar 28;8:163
pubmed: 28400731
Cardiol Young. 2018 May;28(5):739-742
pubmed: 29455693
Ital J Pediatr. 2018 Aug 30;44(1):103
pubmed: 30157893
Ital J Pediatr. 2018 Aug 30;44(1):102
pubmed: 30157897